Aurobindo Pharma Limited Buyback (Aurobindo Pharma Buyback 2024) Detail

Last date to be eligible to participate in buyback is July 29, 2024.

The Aurobindo Pharma Buyback 2024 is a Tender Offer.

Sorry the Aurobindo Pharma Buyback 2024 timelines are not available at this time.

The Aurobindo Pharma Buyback 2024 is being offered at Rs ₹1460 per share per equity share.

The record date for the Aurobindo Pharma Buyback 2024 is July 30, 2024.

The issue size of Aurobindo Pharma Buyback 2024 is of 5,136,986 equity shares at ₹1460 per share aggregating upto ₹750.00 Crores.

The Buy-Back is being undertaken, inter-alia, for the following reasons:

1. The buy-back will help the company reward its shareholders and enhance the overall return to shareholders.
2. The buy-back is expected to improve earnings per share and other key ratios such as return on net worth and return on assets over a period of time;
3. The buy-back is being implemented through the tender offer route as prescribed under the buyback regulations and would involve the allocation of the number of equity shares as per their entitlement or 15% of the number of equity shares to be bought back, whichever is higher, reserved for small shareholders.

Letter of Offer

All the eligible Shareholders of the Company holding either Physical Shares or Demat Shares as on the Record Date can participate in the buyback offer through their Stock Broker.

The eligible shareholder holding the shares in Demat form needs to inform their broker the details of the Equity shares they wish to tender in the Buyback Offer. The shareholder needs to transfer the tendered shares to a Special account of the clearing corporation. The broker, in turn, would place an order on the stock exchange for the buyback.

The eligible shareholder holding the shares in physical form needs to approach their broker with original share certificates and supporting documents. Upon completion of document verification, the broker places an order on the stock exchange and submits the original share certificate and TRS to the registrar.

The tender form and TRS are optional in the case of Demat shares but mandatory in the case of physical shares.

The Aurobindo Pharma Buyback 2024 offers an opportunity for the shareholders to exit their positions at a premium price. In case you stay invested you would have an increased percentage of shareholding in the company and improved earnings per share. Thus, one should understand the company fundamentals along with one's need, goals, and risk appetite to decide if one wants to stay invested or participate in the buyback offer.